Ulimorelin Study of Efficacy and Safety (ULISES 007)

NCT01285570 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Dysmotility

Interventions

DRUG: Ulimorelin Intravenously (IV)
DRUG: Ulimorelin Intravenously (IV)
DRUG: 5% dextrose in water

Sponsor

Tranzyme, Inc.

Collaborators

[object Object]